Vanda Pharmaceuticals (VNDA) Scheduled to Post Earnings on Thursday

Vanda Pharmaceuticals (NASDAQ:VNDAGet Rating) will be posting its quarterly earnings results after the market closes on Thursday, May 5th. Analysts expect Vanda Pharmaceuticals to post earnings of ($0.01) per share for the quarter. Vanda Pharmaceuticals has set its FY 2022 guidance at EPS.

Vanda Pharmaceuticals (NASDAQ:VNDAGet Rating) last released its earnings results on Wednesday, February 23rd. The biopharmaceutical company reported $0.12 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.09 by $0.03. Vanda Pharmaceuticals had a return on equity of 6.81% and a net margin of 12.34%. The company had revenue of $68.02 million during the quarter, compared to the consensus estimate of $65.90 million. During the same quarter in the previous year, the company posted $0.15 EPS. On average, analysts expect Vanda Pharmaceuticals to post $0 EPS for the current fiscal year and $1 EPS for the next fiscal year.

VNDA opened at $10.19 on Friday. Vanda Pharmaceuticals has a 52-week low of $9.98 and a 52-week high of $21.86. The stock has a market capitalization of $569.69 million, a PE ratio of 17.57 and a beta of 0.54. The stock’s 50 day moving average price is $11.47 and its 200-day moving average price is $14.62.

In related news, CMO Joakim Wijkstrom sold 6,974 shares of the company’s stock in a transaction on Wednesday, March 2nd. The stock was sold at an average price of $11.19, for a total value of $78,039.06. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, SVP Timothy Williams sold 12,060 shares of the company’s stock in a transaction on Wednesday, March 2nd. The shares were sold at an average price of $11.09, for a total transaction of $133,745.40. The disclosure for this sale can be found here. Insiders sold 30,015 shares of company stock valued at $334,662 in the last quarter. 6.10% of the stock is owned by company insiders.

Institutional investors and hedge funds have recently modified their holdings of the stock. Barclays PLC lifted its stake in shares of Vanda Pharmaceuticals by 26.1% in the 4th quarter. Barclays PLC now owns 71,641 shares of the biopharmaceutical company’s stock valued at $1,124,000 after purchasing an additional 14,839 shares during the last quarter. BlackRock Inc. lifted its position in shares of Vanda Pharmaceuticals by 1.3% during the 4th quarter. BlackRock Inc. now owns 9,825,375 shares of the biopharmaceutical company’s stock worth $154,158,000 after buying an additional 123,253 shares during the last quarter. Goldman Sachs Group Inc. lifted its position in shares of Vanda Pharmaceuticals by 108.5% during the 4th quarter. Goldman Sachs Group Inc. now owns 1,701,256 shares of the biopharmaceutical company’s stock worth $26,693,000 after buying an additional 885,431 shares during the last quarter. California State Teachers Retirement System lifted its position in shares of Vanda Pharmaceuticals by 2.1% during the 4th quarter. California State Teachers Retirement System now owns 76,548 shares of the biopharmaceutical company’s stock worth $1,201,000 after buying an additional 1,590 shares during the last quarter. Finally, Parametric Portfolio Associates LLC raised its position in Vanda Pharmaceuticals by 9.9% in the 4th quarter. Parametric Portfolio Associates LLC now owns 287,391 shares of the biopharmaceutical company’s stock valued at $4,509,000 after purchasing an additional 25,937 shares during the last quarter. Hedge funds and other institutional investors own 99.12% of the company’s stock.

Several brokerages have recently issued reports on VNDA. StockNews.com upgraded shares of Vanda Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Saturday, March 26th. Zacks Investment Research raised shares of Vanda Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, March 8th. TheStreet lowered shares of Vanda Pharmaceuticals from a “b-” rating to a “c” rating in a research report on Wednesday, February 9th. Finally, Jefferies Financial Group lowered shares of Vanda Pharmaceuticals from a “buy” rating to a “hold” rating and dropped their price target for the stock from $24.00 to $12.00 in a research report on Friday, February 25th. Two analysts have rated the stock with a hold rating and two have given a buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Buy” and a consensus price target of $18.00.

About Vanda Pharmaceuticals (Get Rating)

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs. The company's marketed products include HETLIOZ for the treatment of non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.

Read More

Earnings History for Vanda Pharmaceuticals (NASDAQ:VNDA)

Receive News & Ratings for Vanda Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.